Borderline resectable pancreatic adenocarcinoma, is conversion therapy realistic?

References

• Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA 2013;310:1473–81.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial. JAMA 2012;308:147–56.
   PubMed Web of Science ®Google Scholar
• Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049–57.
   PubMed Web of Science ®Google Scholar
• Millikan KW, Deziel DJ, Silverstein JC, Kanjo TM, Christein JD, Doolas A, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999;65:618–23; discussion 23–4.
   PubMed Web of Science ®Google Scholar
• Takai S, Satoi S, Toyokawa H, Yanagimoto H, Sugimoto N, Tsuji K, et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: A retrospective, single-institution experience. Pancreas 2003;26:243–9.
   PubMed Web of Science ®Google Scholar
• Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004;40:549–58.
   PubMed Web of Science ®Google Scholar
• Gillen S, Schuster T, Meyer zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267.
   PubMed Web of Science ®Google Scholar
• Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3496–502.
   PubMed Web of Science ®Google Scholar
• Lind PA, Isaksson B, Almstrom M, Johnsson A, Albiin N, Bystrom P, et al. Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma. Acta Oncol 2008;47:413–20.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364: 1817–25.
   PubMed Web of Science ®Google Scholar
• Hartlapp I, Muller J, Kenn W, Steger U, Isbert C, Scheurlen M, et al. Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy. Onkologie 2013;36:123–5.
   PubMedGoogle Scholar
• Faisal F, Tsai HL, Blackford A, Olino K, Xia C, De Jesus-Acosta A, et al. Longer course of induction chemotherapy followed by chemoradiation favors better survival outcomes for patients with locally advanced pancreatic cancer. Am J Clin Oncol Epub 2013 Dec 17.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE, Wolf R, et al. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol 2012;16:29–37.
   PubMed Web of Science ®Google Scholar
• Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, et al. Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol 2011;18:3601–7.
   PubMed Web of Science ®Google Scholar
• Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17:500–3.
   PubMed Web of Science ®Google Scholar
• Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009;27:1806–13.
   PubMed Web of Science ®Google Scholar
• Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javie MM, Safran H, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011;29:3037–43.
   PubMed Web of Science ®Google Scholar
• Lopez-Casas PP, Lopez-Fernandez LA. Gene-expression profiling in pancreatic cancer. Expert Rev Mol Diagn 2010; 10:591–601.
   PubMed Web of Science ®Google Scholar